Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
The East Asian Parkinson Disease Genomics Consortium4306
Implications of the KIWE trial for low-income and lower-middle-income countries965
Multidisciplinary care for amyotrophic lateral sclerosis633
Lessons and future directions for GBA1-targeting therapies632
New therapies for Pompe disease: are we closer to a cure?602
Dementia diagnosis in the anti-amyloid era602
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease482
Traumatic brain injury research: homogenising heterogeneity463
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply420
Correction to Lancet Neurol 2024; 23: 168–77381
Correction to Lancet Neurol 2022; 21: 42–52378
Correction to Lancet Neurol 2021; 20: 448–59373
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study368
The predictive value and clinical use of the neurological pupillary index – Authors' reply355
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study347
The relevance of social and commercial determinants for neurological health326
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study274
Global burden of stroke: dynamic estimates to inform action268
RAB32 mutation in Parkinson's disease259
Pseudomedicine for sports concussions in the USA245
Increasing diversity in dementia research244
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial244
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study241
Anti-CD19 CAR T cells for refractory myasthenia gravis235
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r231
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study221
A biological classification of Huntington's disease: the Integrated Staging System201
Management of atherosclerotic extracranial carotid artery stenosis190
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial189
A chilly tale of dementia188
A sensitive portrayal of a controversial condition185
Trials in intracerebral haemorrhage: a path to success?185
A study in healing the wounds of trauma178
Beyond the modular brain173
Epilepsy syndromes: an essential piece of the puzzle173
Elia M Pestana Knight170
Delving into the human mind167
Albert Kwaku Akpalu161
A blood test for Alzheimer's disease: a step forward157
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial153
Surrogate endpoints for progressive multifocal leukoencephalopathy148
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri148
Safe laboratory management of prions and proteopathic seeds144
Diana Cejas143
Considering the neurological health needs of LGBTQIA people141
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial139
Diversity and inclusion in neurosurgery139
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply139
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study137
Movement disorders research in 2021: cracking the paradigm137
Parkinson's disease is a recognisable and useful diagnostic entity131
Gene therapy for X-linked myotubular myopathy: the challenges127
Correction to Lancet Neurol 2022; 21: 284–94124
Correction to Lancet Neurol 2023; 22: 812–25123
Aspiring to restore arm and hand function after stroke123
Amyotrophic lateral sclerosis from genotoxins alone?121
A nasal CGRP receptor antagonist for acute migraine therapy121
Development of treatments for Down syndrome118
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment116
From stroke awareness to stroke action awareness114
The prescription of valproate: risk of harm113
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro106
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases104
Encephalitis awareness: our ambitious global endeavour103
Better buildings for elderly people to thrive102
Poldi Wilbrink102
New results for risdiplam in spinal muscular atrophy98
Expansion of stenting indications in the USA98
Correction to Lancet Neurol 2021; 20: 687–8997
Neurological infections in 2023: surveillance and prevention95
Jessica Ailani91
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial90
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial89
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study88
α-synuclein seed amplification and its uses in Parkinson's disease87
A proposal for equity neuroscience87
Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies87
Spontaneous intracranial hypotension: searching for the CSF leak87
Multiple sclerosis in 2022: old players, new insights86
Brain health in the Philippines86
Correction to Lancet Neurol 2024; 23: 110–2285
Correction to Lancet Neurol 2022; 21: 620–3185
In search of Charcot's second sight84
Detection of ionising radiation by the CNS: a case report83
0.089387893676758